AKT1 and prostate carcinoma: Treating prostate cancer cells with PI3K and Akt inhibitors or transfecting them with PI3K and Akt siRNAs reversed apelin-mediated effects upon TIMP2 synthesis, cell motility and miR-106a-5p synthesis (Figure 6A–H).